Literature DB >> 18393846

The other side of the opioid story: modulation of cell growth and survival signaling.

Yulong L Chen1, Ping Yee Law, Horace H Loh.   

Abstract

Opioids have been used as pain control medications for thousands of years. Opioids are highly effective analgesics clinically available for controlling moderate and severe pain. Recent genetic knockout and knockin studies have definitively demonstrated that the analgesic effect is mediated through opioid receptors. In addition to their analgesic effect, opioids also have the potential to develop tolerance and physical dependence. Moreover, opioids can modulate cell proliferation and survival. Attempts to design better opioid drugs to eliminate or diminish these undesirable effects for clinical benefits have achieved limited success. In recent years, investigation of the effects of opioid-mediated cell proliferation and survival has been very active, resulting in many publications. However, the molecular targets of such non-analgesic effects are complex. Several important pathways that control cell proliferation, survival, and apoptosis have been reported to be associated with the non-analgesic effects, which may be mediated through both opioid receptor signaling and other non-opioid receptor molecular entity-mediated signaling. This review tries to bring the attention of the medicinal chemistry community to new developments and advances in the research areas of opioid-mediated cell proliferation and survival. Further investigation of the molecular mechanism of these non-analgesic opioid effects may eventually yield useful information such as new drug targets, which may be explored to benefit for clinical treatments such as targeted cancer therapy, cancer pain management, regeneration of neurons, and recovery from drug addiction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393846     DOI: 10.2174/092986708783955518

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  12 in total

1.  Sedation and analgesia in mechanically ventilated preterm neonates: continue standard of care or experiment?

Authors:  Christopher McPherson
Journal:  J Pediatr Pharmacol Ther       Date:  2012-10

Review 2.  Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.

Authors:  Wakako Fujita; Ivone Gomes; Lakshmi A Devi
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 3.  Opioid receptor heteromers in analgesia.

Authors:  Cristina M Costantino; Ivone Gomes; Steven D Stockton; Maribel P Lim; Lakshmi A Devi
Journal:  Expert Rev Mol Med       Date:  2012-04-10       Impact factor: 5.600

4.  Delta receptors are required for full inhibitory coupling of mu-receptors to voltage-dependent Ca(2+) channels in dorsal root ganglion neurons.

Authors:  Wendy Walwyn; Scott John; Matthew Maga; Christopher J Evans; Tim G Hales
Journal:  Mol Pharmacol       Date:  2009-04-08       Impact factor: 4.436

Review 5.  Infant pain management: a developmental neurobiological approach.

Authors:  Maria Fitzgerald; Suellen M Walker
Journal:  Nat Clin Pract Neurol       Date:  2009-01

Review 6.  The role of morphine in regulation of cancer cell growth.

Authors:  Katarzyna Gach; Anna Wyrębska; Jakub Fichna; Anna Janecka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-29       Impact factor: 3.000

7.  Effects of sufentanil on human gastric cancer cell line SGC-7901 in vitro.

Authors:  Weidong Wu; Ningxian Wei; Chun-Nan Jiang; Suyang Cui; Jintao Yuan
Journal:  Cent Eur J Immunol       Date:  2014-10-14       Impact factor: 2.085

8.  Crosstalk between delta opioid receptor and nerve growth factor signaling modulates neuroprotection and differentiation in rodent cell models.

Authors:  Dwaipayan Sen; Michael Huchital; Yulong L Chen
Journal:  Int J Mol Sci       Date:  2013-10-21       Impact factor: 5.923

9.  Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network.

Authors:  Inka Regine Weingaertner; Sarah Koutnik; Hermann Ammer
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

10.  Curbing inflammation in burn patients.

Authors:  Jayme A Farina; Marina Junqueira Rosique; Rodrigo G Rosique
Journal:  Int J Inflam       Date:  2013-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.